AdvanCell’s Series D financing adds to a growing pattern: investors are funding not just candidates but also manufacturing capacity required to deliver radiopharmaceuticals at scale. The $315 million round is explicitly tied to studying a lead prostate cancer radioligand candidate while expanding US manufacturing for radioactive therapy delivery. The funding package underscores a constraint that has been repeatedly flagged across the sector—late-stage execution is gated by dose production and reliable supply for short-lived isotopes. By coupling clinical and manufacturing investment, the company aims to reduce bottlenecks that can otherwise delay pivotal timelines. For industry professionals, the signal is that manufacturing readiness is increasingly treated as an investable asset alongside clinical development risk.